EVERFORTUNE.AI announced that it has signed a 15-year technology transfer and co-development plan with a nephrology company under Temasek Holdings, which is expected to generate at least US$37.22-38.12 million in revenue (approximately NT$1.116 billion-1.143 billion). With a positive business outlook, EVERFORTUNE.AI is aiming to be traded as emerging stocks in the first quarter of this year to enter the capital market.

The company's revenue for 2022 will be $53 million, an annual growth of 40.9%, and its net loss per share for the first three quarters will be $0.49. The company is optimistic that it will turn a profit in 2023.

The company was founded in 2018 to target difficult markets and technical challenges, setting up platforms for big data, medical artificial intelligence and cloud-based biomedicine, in recognition of Taiwan's important role in the global digital health sector. The integration of these three platforms can be used as a synergy, just like Apple's concept from IOS to mobile phones and brand shops, which is difficult and challenging, but can provide the services that customers need most.

With a strong shareholder base, EVERFORTUNE.AI 's major shareholders include Trend Micro, Quanta, Center Ventures and so on, all of which are regular customers in digital health.

EVERFORTUNE.AI has received six digital health related approvals from FDA, ten from TFDA, and 21 patents from various countries, and has customers in the U.S., France, Singapore, Hong Kong, China, and Taiwan.

The company has signed what is likely to be the largest technology transfer and co-development project in Taiwan in the field of medical artificial intelligence with a nephrology company that is a portfolio company of Temasek, and is expected to generate US$37.22-38.12 million in revenue in the future, excluding royalties.